What have we learned from 20 tumultuous years of patent law in the life sciences? Is patenting likely to be as important for the industry in the future?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The Bermuda Triangle: The Pragmatics, Policies, and Principles for Data Sharing in the History of the Human Genome Project
Journal of the History of Biology Open Access 02 November 2018
-
Evidence of insufficient quality of reporting in patent landscapes in the life sciences
Nature Biotechnology Open Access 07 March 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Heller, M.A. & Eisenberg, R.S. Science 280, 698–701 (1998).
Rai, A. Duke Law J. 61, 1237–1281 (2012).
Cook-Deegan, R., Chandrasekharan, S. & Angrist, M. Nature 458, 405–406 (2009).
Hemphill, C.S. & Sampat, B. Science 339, 1386–1387 (2013).
Kapczynski, A. N. Engl. J. Med. 373, 201–203 (2015).
Novartis AG v. Union of India, Civil Appeal No. 2706–2716 (Supreme Court of India, 2013).
Bessen, J. & Meurer, M. Patent Failure (Princeton Univ., 2008).
132 S. Ct. 1289 (2012).
133 S. Ct. 2107 (2013).
788 F.3d 1371 (Fed. Cir. 2015).
133 S. Ct. 2223 (2013).
Merges, R.P. Berkeley Technol. Law J. 27, 1023–1046 (2012).
Hemphill, T.P. Regulation 38, 6–8 (2015).
Rai, A.K. & Sherkow, J.S. Letter to US Senate Committee on the Judiciary Concerning Inter Partes Review and Orange Book-Listed Patents http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2623736 (June 18, 2015).
Eisenberg, R. & Crane, D. Mich. Telecomm. Tech. Law Rev. 21, 197–262 (2015).
Grabowski, H. et al. FDA Law J. 67, 373–391 (2012).
Sharfstein, J. J. Am. Med. Assoc. 313, 667–668 (2015).
FDA Fed. Regist. 79, 59776–59779 (2014).
USPTO. Fed. Regist. 97, 74618–74633 (2014).
DiMasi, J.A., Grabowski, H.G. & Hansen, R.W. Innovation in the pharmaceutical industry: new estimates of R&D costs http://csdd.tufts.edu/news/complete_story/cost_study_press_event_webcast (Tufts Center for the Study of Drug Development, Boston, November 18, 2014).
Public Law No. 111–148, 124 Stat. 199 (2010).
Price, W.N. II & Rai, A.K. Science 348, 188–189 (2015).
Cook-Deegan, R., Conley, J.M., Evans, J.P. & Vorhaus, D. Eur. J. Hum. Genet. 21, 585–588 (2013).
Micheel, C. M, Nass, S.J. & Omenn, G.S. (eds.) Evolution of Translational Omics: Lessons Learned and the Path Forward (Institute of Medicine, The National Academies Press, Washington, 2012).
Brüstle v. Greenpeace eV, Opinion of Advocate General. Case C-34/10 (CJEU Mar. 10, 2011).
Int'l Stem Cell Corp. v. Comptroller Gen. of Patents. Case C-364/13 (CJEU Dec. 18, 2014).
28 U.S.C. § 1498.
Sherkow, J.S. Wash. Law Rev. 90, 205–269 (2015).
Reichman, J.H. J. Law Med. Ethics 37, 247–263 (2009).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Rai, A., Sherkow, J. The changing life science patent landscape. Nat Biotechnol 34, 292–294 (2016). https://doi.org/10.1038/nbt.3504
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3504
This article is cited by
-
Was the Myriad decision a 'surgical strike' on isolated DNA patents, or does it have wider impacts?
Nature Biotechnology (2018)
-
The Bermuda Triangle: The Pragmatics, Policies, and Principles for Data Sharing in the History of the Human Genome Project
Journal of the History of Biology (2018)
-
After Myriad, what makes a gene patent claim 'markedly different' from nature?
Nature Biotechnology (2017)
-
Evidence of insufficient quality of reporting in patent landscapes in the life sciences
Nature Biotechnology (2017)